Project Grant K99AI192941
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $100,228 on November 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). MIT will conduct research examining the molecular basis of T cell allorecognition in graft-versus-host disease and graft-versus-leukemia. The research uses a repertoire-scale examination to determine the molecular mechanisms underlying T cell recognition of non-self major...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases awarded $233,250 to the University of Maryland, Baltimore on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on how Rickettsia species manipulate macrophage antimicrobial responses through engagement of the CD300F efferocytic receptor to facilitate host infection. The research addresses the gap in understanding rickettsial pathogenesis mechanisms that has hindered development of...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology (MIT) $553,136 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research visualizing HIV-1 capsid passage through the nuclear pore complex. The funded work addresses how HIV-1 traverses the nuclear pore complex during viral entry into the cell nucleus, a critical stage in the infection process preceding uncoating, reverse transcription, and...
- The National Institute of Allergy and Infectious Diseases awarded Whitehead Institute for Biomedical Research $899,850 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how apicomplexan parasites recognize and invade host cells. The funded research examines the molecular mechanisms by which parasites such as Toxoplasma and Plasmodium trigger rhoptry discharge—the secretion of proteins from specialized organelles upon contact with host...
- The National Institute of Allergy and Infectious Diseases awarded Old Dominion University $1.322 million in funding on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms by which pathogenic Rickettsia species manipulate macrophage mitochondrial function and evade host immune responses. The award funds two research aims: determining how pathogenic spotted fever group rickettsia remodel mitochondrial dynamics in macrophages through...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts Institute of Technology $424,265 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 7, 2025, for a project period extending through July 31, 2027. The project develops an integrated Density-shift Immunocapture Separation-Raman (DIMS-RAMAN) platform designed to rapidly isolate and analyze bacterial pathogens from blood samples within approximately 1-2...
- The National Institute of Allergy and Infectious Diseases awarded Boston College $465,000 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research into the evolution-inspired molecular basis of fungal recognition by mammalian immune receptors. The project applies evolutionary frameworks to understand how mammalian innate immune systems recognize and respond to pathogenic fungi. The research combines testing of naturally diversified immune...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $267,000 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research decoding gasdermin D (GSDMD) pore clustering as a regulatory checkpoint controlling pyroptosis, a lytic and inflammatory form...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $807,481 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate human immune responses in acute spotted fever group rickettsioses and develop host response-based diagnostics. The project characterizes the human immune response to spotted fever group rickettsioses across three distinct geographic settings—Sri Lanka, Tanzania, and the United States—and develops...
The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $185,472 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on molecular host determinants of spotted fever group rickettsial infection. The funded research addresses host-pathogen interactions in Rickettsia species, obligate intracellular bacterial pathogens that cause tickborne vascular endothelial diseases with rising global incidence in the 21st century. The project applies genome-scale screening and host-directed perturbation techniques to identify and characterize host factors that regulate mammalian cell infection by Rickettsia parkeri, a model spotted fever group species. Research aims include dissecting a newly discovered host-pathogen interaction axis involving the host proline isomerase PPIA/cyclophilin A and the R. parkeri surface virulence factor SCA2, and deciphering how competing lipid biosynthesis pathways interact during infection while profiling broader host metabolic responses to R. parkeri infection. Performance of work occurs at MIT's Cambridge, Massachusetts location. The project period runs through June 30, 2028. The award is classified as a Project Grant, an assistance type supporting investigator-initiated biomedical research training and development in infectious diseases and related immunologic and allergic disease areas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $185.5k | 8/18/26 |